Patent details
300702
Product Name:
Vedolizumab
The time of generation of the report may vary depending on the number of the selected files and the pages of each file. If the generation of the consolidated PDF file takes long, you may reduce the number of selected files and proceed with the generation of the PDF in batches.
Ok
Cancel
You have not selected any documents
Ok
Basic Information
Publication number:
300702
Type:
Certificate
SPC Type:
Medical
Basic Patent Number:
EP1278543
Status:
SPC in force
Application number:
300702
Procedural language:
Dutch
First Applicant Residence Country:
Marketing Authorization
Marketing Authorization Number:
EU/1/14/923
Marketing Authorization Type:
EEA
Marketing Authorization Date:
27/05/2014
Marketing Authorization Country:
European Union (EU)
Dates
Filing date:
11/11/2014
First Marketing Authorization date:
27/05/2014
Grant date:
28/01/2016
Activation date:
13/04/2021
Lapsed By Non Payment Annual Fee Date:
Renunciation Date:
NullificationDate:
Registration date:
11/11/2014
SPC/SPC Extension Expiration Date:
12/04/2026
Lapsed By Expiration Date:
Withdrawal date:
Revocation Date:
Invalidity Date:
Withdrawal Market Authorization Date:
Refusal Date:
Applicant/holder
From:
23/03/2022
Name:
Genentech, Inc.
Address:
1 DNA Way, SOUTH SAN FRANCISCO, CA 94080-4990, United States of America (US)
From:
23/03/2022
Name:
Takeda Pharmaceutical Company Limited
Address:
1-1 Doshomachi 4-chome Chuo-ku
Osaka-shi, 541-0045, Osaka , Japan (JP)
Historical Applicant/holder
From:
23/03/2022
To:
23/03/2022
Name:
MILLENNIUM PHARMACEUTICALS, INC.
Address:
40 Landsdowne Street, 02139, Cambridge, MA, United States of America (US)
From:
11/11/2014
To:
23/03/2022
Name:
MILLENNIUM PHARMACEUTICALS, INC.
Address:
75 Sidney Street, CAMBRIDGE, MASSACHUSETTS 02139, United States of America (US)
From:
11/11/2014
To:
23/03/2022
Name:
Genentech, Inc.
Address:
1 DNA Way, SOUTH SAN FRANCISCO, CA 94080-4990, United States of America (US)
Agent
Name:
ir. M.F.J.M. Ketelaars c.s.
From:
11/11/2014
Address:
NLO
Postbus 29720, 2502 LS, Den Haag, Netherlands (NL)
To:
Publication
Bulletin
1
Bulletin Heading:
CO
Journal edition number:
17/22
Publication date:
29/04/2022
Description:
Changes in the Netherlands Patent Register
2
Bulletin Heading:
SPC
Journal edition number:
15/21
Publication date:
14/04/2021
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
3
Bulletin Heading:
SPC
Journal edition number:
05/16
Publication date:
03/02/2016
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
4
Bulletin Heading:
SPC
Journal edition number:
2014/48
Publication date:
26/11/2014
Description:
Applications and granted Supplementary Protection Certificates (or the extensions of the Supplementary Protection Certificates)
Deed
Change of Address
Change Kind/ Decision Type:
Owner
Deed Number:
RC202200726A
Date Registered:
23/03/2022
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Change of owner(s)
Change Kind/ Decision Type:
Assignment
Deed Number:
RC202200726B
Date Registered:
23/03/2022
License Effective Date:
License Expiration Date:
Scope of License:
Deed Filer:
dr. R.C. van Duijvenbode c.s.
Journal Edition Number:
Text:
Deed Status:
Country Code:
Updated License Number:
Terminated License Number:
Added Owner(s)
1
Name:
Genentech, Inc.
Address:
1 DNA Way, SOUTH SAN FRANCISCO, CA 94080-4990, United States of America (US)
2
Name:
Takeda Pharmaceutical Company Limited
Address:
1-1 Doshomachi 4-chome Chuo-ku
Osaka-shi, 541-0045, Osaka , Japan (JP)
Changed Pledgee
Name:
Address:
Removed Usufructuary
Name:
Address:
Added Usufructuary
Name:
Address:
Changed Usufructuary
Name:
Address:
Annual Fee
Annual Fee(s) Due Date:
Annual Fee Number:
Last Annual Payment Date:
09/04/2025
Last Annual Fee Paid Number:
25
Last Annual Fee Paid Amount:
2400 Euro
Payer:
NLO
Filing date
Document type
Document Description
Number of pages
File Type
28/01/2016
Outgoing Correspondence
Outgoing Letter
1
PDF
/2/0/7/0/0/0400300702/docs/300702_3_outgoingcorrespondence20201019032530096.pdf
28/01/2016
SPC Documents
Certificate SPC
1
PDF
/2/0/7/0/0/0400300702/docs/300702_4_supplprotectioncertificate20201019032355989.pdf
04/05/2015
Incoming Correspondence Paper
Accompanying letter incoming document
2
PDF
/2/0/7/0/0/0400300702/docs/300702_1_incomingcorrespondencepaper20150504.pdf
26/03/2015
Outgoing Correspondence
Outgoing Letter
1
PDF
/2/0/7/0/0/0400300702/docs/300702_2_outgoingcorrespondence20150326.pdf
04/03/2015
Incoming Correspondence Electronic
Accompanying letter incoming document
1
PDF
/2/0/7/0/0/0400300702/docs/300702_8_incomingcorrespondenceelectronic20201019030127909.pdf
04/12/2014
Outgoing Correspondence
Outgoing Letter
2
PDF
/2/0/7/0/0/0400300702/docs/300702_0_outgoingcorrespondence20141204.pdf
17/11/2014
Outgoing Correspondence
Outgoing Letter
1
PDF
/2/0/7/0/0/0400300702/docs/300702_5_outgoingcorrespondence20141117.pdf
11/11/2014
SPC Documents
Annex SPC
3
PDF
/2/0/7/0/0/0400300702/docs/300702_6_supplprotectioncertificate20201019025831426.pdf
11/11/2014
SPC Documents
Summary of the characteristics of the product
21
PDF
/2/0/7/0/0/0400300702/docs/300702_7_supplprotectioncertificate20201019025646524.pdf
11/11/2014
SPC Documents
Marketing Authorization SPC
4
PDF
/2/0/7/0/0/0400300702/docs/300702_9_supplprotectioncertificate20201019021134447.pdf
11/11/2014
Application Form
First filed application form
2
PDF
/2/0/7/0/0/0400300702/docs/300702_10_applicationform20141111.pdf